Journal of Crohn s and Colitis · 2018 · 48 citations · 24 references
Life SciencesCell BiologyImmunologyImmunotherapyInflammationInnate ImmunityCytokine BiologyCytokine SignalingGastrointestinal InflammationInflammatory Bowel DiseaseInflammatory SignalingMacrophage BiologyImmune Complex FormationInnate Immune CytokinesInterleukin 23 InhibitionMacrophage Cytokine ProductionMacrophage Cytokine RegulationMacrophage Fc Receptor SignalingMacrophage-mediated InflammationSize-exclusion Liquid Chromatography
BACKGROUND AND AIMS: We have recently shown that the mode of action of IgG1 anti-tumour necrosis factor [TNF] antibodies in inflammatory bowel disease [IBD] requires Fcγ-receptor [FcγR] engagement on macrophages. Here we examine the effect of Fcγ-receptor signalling by anti-TNF on macrophage IL-12/IL-23 secretion. METHODS: Cytokine production by human inflammatory macrophages was assessed at the level of RNA and protein. TNF-anti-TNF immune complex formation was determined by size-exclusion chromatography and signalling visualized by immunofluorescence. IL-12/IL-23p40 was measured in CD14+ lamina propria cells from IBD patients. RESULTS: Infliximab and adalimumab potently suppressed IL-12/IL-23 production by inflammatory macrophages, but Fab' fragment certolizumab did not. IL-12/IL-23 suppression depended on Syk activity and was mediated at the level of IL-12/IL-23p40 mRNA. Etanercept, a soluble TNF receptor fused to an Fc-region, did not inhibit IL-12/L-23 secretion, suggesting that the presence of an Fc-region was not sufficient. Infliximab and adalimumab formed immune complexes with soluble TNF whereas etanercept did not, suggesting that FcγR-mediated suppression of IL-12/IL-23 required the formation of immune complexes. Indeed, non-specific IgG1 immune complexes, but not uncomplexed IgG1, similarly suppressed IL-12/IL-23 secretion. Finally, infliximab significantly decreased IL-12/IL-23p40 production in myeloid cells isolated from the lamina propria of IBD patients. CONCLUSIONS: TNF-anti-TNF antibody immune complexes potently inhibit IL-12/IL-23 expression by inflammatory macrophages. Our data suggest that anti-TNFs and antibodies against IL-12/IL-23 may therefore have partially overlapping modes of action in patients with IBD.
24
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn, Brian G. Feagan, Paul Rutgeerts et al. · New England Journal of Medicine · 2013 · 2.7K citations · Full text
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Brian G. Feagan, William J. Sandborn, Christopher Gasink et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text
Certolizumab Pegol for the Treatment of Crohn's Disease
William J. Sandborn, Brian G. Feagan, S Stoĭnov et al. · New England Journal of Medicine · 2007 · 1.1K citations · Full text